TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 Monotherapy

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 11, 2021

Primary Completion Date

September 30, 2024

Study Completion Date

March 31, 2025

Conditions

Solid Tumor

Interventions

BIOLOGICAL

TILT-123

TNFalpha and IL-2 coding oncolytic adenovirus TILT-123

Trial Locations (2)

RECRUITING

Helsinki University Hospital, Helsinki

RECRUITING

Docrates Cancer Center, Helsinki

All Listed Sponsors

lead

TILT Biotherapeutics Ltd.

INDUSTRY

NCT04695327 - TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 Monotherapy | Biotech Hunter | Biotech Hunter